Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Relapsed/Refractory Ovarian Carcinoma
Interventions: NTB-928; Drug
Lead sponsor: TeneoSeven, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more

Conditions: Acute Leukemia, Myelodysplasia
Interventions: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Year to 65 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 28
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 22 more

Conditions: Obesity, Tuberculosis
Interventions: Ethambutol; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Clinical Pharmacology
Interventions: Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anorexia Nervosa
Interventions: Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA); Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: NP-101, Placebo; Drug · Other
Lead sponsor: Novatek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more

Conditions: Osteosarcoma
Interventions: Mifamurtide (L-MTP-PE); Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 50 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Interventions: AIV007; Drug
Lead sponsor: AiViva BioPharma, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more

Conditions: Severe to Critical COVID 19 With Associated ARDS
Interventions: FP-025 100 mg, FP-025 300 mg, Placebo; Drug
Lead sponsor: Foresee Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more

Conditions: Type 2 Diabetes Mellitus, Bone Remodeling
Interventions: exenatide, Saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 45 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mucositis, Pain, Leukemia
Interventions: Real Acupuncture, Sham Acupuncture; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain and Central Nervous System Tumors
Interventions: temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more

Conditions: Brain Cancer
Interventions: erlotinib, Cytoreductive Surgery; Drug · Procedure
Lead sponsor: Andrew B Lassman, MD; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: HIV Infection
Interventions: Atazanavir + Ritonavir + Combivir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: West Palm Beach, Florida • Houston, Texas

Conditions: Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions: LHP588, Placebo Drug; Drug
Lead sponsor: Lighthouse Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Murrieta, California + 34 more

Conditions: Resistant Hypertension
Interventions: Placebo, TBC3711; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 9 more

Conditions: Vasoconstriction, Vasodilation
Interventions: Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside; Other · Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Tennis Elbow
Interventions: TenoMiR, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: Causeway Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Redwood City, California • New York, New York

Conditions: Mature Cataracts
Interventions: DYME; Drug
Lead sponsor: Aqumen Biopharmaceuticals, N.A.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Fayetteville, Arkansas • Inglewood, California • Sacramento, California + 13 more

Conditions: Post Liver Transplant
Interventions: EnvarsusXR, Tacrolimus; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Fenofibric Acid 105 mg Tablet; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Opiate-related Disorders
Interventions: Buprenorphine/naloxone, Methadone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 1,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 9
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 6 more

Search by objective public record fields.

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Study of NTB-928 in R/R OC

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Acupuncture for Mucositis Pain in Cancer Care

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant

Four Arm Food Effect Study of Fenofibric Acid Tablets

Starting Treatment With Agonist Replacement Therapies (START)